Does resistance training ameliorate cancer-related fatigue in cancer survivors? A systematic review with meta-analysis.

This is a systematic review and meta-analysis — meaning the authors pooled data from multiple existing randomised controlled trials (RCTs) to get a more precise estimate of whether resistance training (RT) reduces cancer-related fatigue (CRF).

**Intervention:** Resistance training (also called strength training or weight training) — defined as exercises where muscles work against an external resistance (free weights, machines, resistance bands, or bodyweight). The minimum duration was 6 weeks. Programs varied widely: 2–3 sessions per week, 1–4 sets per exercise, 8–17 repetitions per set, at intensities ranging from 50–80% of one-repetition maximum (1RM).

**Comparators:** Control groups received usual care, no exercise, or stretching/relaxation sessions. Some studies used wait-list controls (participants got the intervention after the study ended).

**Outcome measures:** Two validated patient-reported outcome measures (PROMs) for fatigue:

**FACIT-F** (Functional Assessment of Chronic Illness Therapy – Fatigue): A 13-item questionnaire measuring physical and functional fatigue over the past 7 days. Higher scores = less fatigue (range 0–52).

**PFS-R** (Piper Fatigue Scale – Revised): A 22-item scale measuring behavioural, affective, sensory, and cognitive dimensions of fatigue. Lower scores = less fatigue (range 0–10).

**Secondary aims:** To see if the effect depended on RT frequency, intensity, volume, or cancer type.

**Total sample across 8 studies:** 1,147 cancer survivors (all had completed primary treatment — surgery, chemotherapy, radiation — and were not on active treatment).

**Breakdown by cancer type:**

5 studies: breast cancer survivors (BCS) — the majority

2 studies: prostate cancer survivors (PCS)

1 study: endometrial cancer survivors (ECS)

**Age range:** Mean ages across studies ranged from 48 to 72 years.

**Gender:** Mostly female (due to breast and endometrial cancer studies), with two studies including only men (prostate cancer).

**Setting:** All studies were conducted in outpatient or community settings (university labs, cancer rehabilitation centres, community gyms). All participants were post-treatment survivors — not currently undergoing chemotherapy or radiation.

**Exclusion criteria:** Advanced/metastatic cancer, non-curative treatment, uncontrolled comorbidities, or inability to exercise safely.

**Key limitation for generalisability:** No studies included lung, colorectal, pancreatic, or haematological cancer survivors. No studies included people currently on active treatment (chemo/radiation). This means the results apply to survivors who have finished primary treatment — not to people currently undergoing therapy.

**Primary outcome:** Cancer-related fatigue, measured via two validated questionnaires:

1. **FACIT-F (Functional Assessment of Chronic Illness Therapy – Fatigue)**

- 13 items, each scored 0–4

- Total range: 0–52

- Higher score = LESS fatigue (better)

- Measures: physical fatigue, functional fatigue, social/family well-being

- Clinically meaningful improvement: ≥3-point change

2. **PFS-R (Piper Fatigue Scale – Revised)**

- 22 items, each scored 0–10

- Total range: 0–10

- Lower score = LESS fatigue (better)

- Measures four dimensions: behavioural/severity, affective meaning, sensory, cognitive/mood

- Cut-offs: 0 = none, 1–3 = mild, 4–6 = moderate, 7–10 = severe

**Methodological quality assessment:** Used the PEDro scale (Physiotherapy Evidence Database), scored out of 10. Scores of 6–8 = "good" quality, 4–5 = "fair", ≤3 = "poor". The included studies scored between 4 and 8 (mean ~6), meaning most were "fair" to "good" quality.

**Statistical approach:**

Random-effects meta-analysis (accounts for variation between studies)

Standardised Mean Difference (SMD) as the effect size

SMD of 0.2 = small, 0.5 = moderate, 0.8 = large (Cohen's conventions)

Heterogeneity assessed using I² statistic (0–40% = low, 30–60% = moderate, 50–90% = substantial, 75–100% = significant)

Sensitivity analysis using leave-one-out method (removing one study at a time to check if results hold)

**Study design:** This is a systematic review with meta-analysis — meaning the authors searched multiple databases for all relevant RCTs, assessed their quality, and statistically combined their results. This is the highest level of evidence for intervention effectiveness (stronger than any single RCT).

**Search strategy:** Four databases (MEDLINE, CINAHL, EMBASE, Cochrane Library) plus PubMed and Google Scholar, searched from inception to June 2022. Search terms: (cancer) AND (fatigue) AND (resistance training) OR (strength training) OR (weight training). Only English-language, human RCTs were included.

**Inclusion criteria:**

RCTs only (not observational studies, case series, or reviews)

Participants ≥18 years, completed primary cancer treatment

Resistance training intervention lasting >6 weeks

Measured fatigue pre- and post-intervention using validated PROMs

Had a control group (usual care, no exercise, or sham exercise)

**Exclusion criteria:**

Advanced/non-curative cancer

Participants currently on active treatment

Non-RCT designs

Interventions <6 weeks

No validated fatigue measure

**What this design can prove:**

A meta-analysis can establish whether an intervention works overall, with greater statistical power than any single study

It can detect patterns across different populations and protocols

It can quantify the size of the effect (not just "it works" but "how much")

It can identify sources of variation (e.g., cancer type, supervision level)

**What this design cannot prove:**

It cannot prove causation at the individual level (that's what the original RCTs do)

It cannot tell you the optimal dose precisely — only that "some RT works better than none"

It cannot tell you about long-term effects beyond the study durations (most were 8–16 weeks)

It cannot tell you about mechanisms (why it works) — only that it does

Publication bias is possible: studies with null results are less likely to be published

**Major methodological weaknesses:**

1. **Small number of studies (only 8)** — limits ability to do subgroup analyses (e.g., by cancer type, dose, supervision)

2. **Heterogeneity in RT protocols** — studies used different exercises, sets, reps, intensities, frequencies, and durations. This makes it hard to prescribe a specific dose.

3. **Most studies focused on breast cancer** — results may not generalise to other cancer types

4. **No blinding of participants or therapists** — impossible in exercise studies. Participants know they're exercising, which can create expectancy effects.

5. **Self-report outcomes only** — no objective measures of fatigue (e.g., actigraphy, physical activity monitors, cognitive tests)

6. **Short follow-up** — no studies measured whether effects persisted after the intervention ended

7. **No intention-to-treat analysis in some studies** — dropouts may bias results

8. **Publication bias not formally assessed** (too few studies for funnel plot analysis)

**Primary outcome — FACIT-F (4 studies, n = 579):**

Resistance training produced a **large, statistically significant reduction in fatigue**

Pooled SMD = 0.932 (95% CI: 0.472 to 1.392), p < 0.001

This means the average person in the RT group had fatigue scores ~0.93 standard deviations better than the average person in the control group

Heterogeneity: I² = 85.6% (substantial) — meaning the effect varied considerably across studies

Sensitivity analysis: removing any single study did not change the overall conclusion (robust finding)

**Primary outcome — PFS-R (4 studies, n = 568):**

Resistance training produced a **moderate, statistically significant reduction in fatigue**

Pooled SMD = −0.622 (95% CI: −1.045 to −0.199), p = 0.004

Negative SMD means less fatigue in the RT group

Heterogeneity: I² = 79.4% (substantial)

Sensitivity analysis: again robust — no single study drove the result

**Subgroup findings (exploratory, not definitive due to small numbers):**

**By cancer type:**

Breast cancer survivors showed the largest and most consistent benefits

Prostate and endometrial cancer survivors showed benefits, but with fewer studies and wider confidence intervals

The authors could not statistically compare cancer types due to insufficient studies

**By supervision:**

**Supervised RT** (in-person, with a trainer) showed larger effects than unsupervised/home-based RT

This was a qualitative observation, not a formal statistical comparison

**By dose (frequency, intensity, volume):**

No clear dose-response relationship could be established

Studies with 2 sessions/week, 2–3 sets of 8–15 reps at 60–80% 1RM tended to show benefits

But the range was too narrow to determine optimal dosing

The authors noted that Brown et al. (2018) found greater fatigue reduction with intensities >60% 1RM compared to lower intensities

**By duration:**

All interventions were ≥6 weeks (range 6–16 weeks)

No clear relationship between duration and effect size, but 12-week programs were most common

**Secondary outcomes (not meta-analysed):**

Quality of life: improved in most studies (not formally pooled)

Muscle strength: improved in all RT groups (expected)

Body composition: mixed results (some showed reduced fat mass, others no change)

**In plain English:**

For the FACIT-F scale (0–52, higher = less fatigue):

The average improvement was about **0.93 standard deviations** — this is considered a "large" effect by standard conventions

To put it in concrete terms: if the average cancer survivor scores ~30 on FACIT-F (moderate fatigue), a large effect might mean an improvement of ~8–12 points — enough to shift from "moderate fatigue" to "mild fatigue" or even "normal"

A 3-point change on FACIT-F is considered clinically meaningful — this effect is 3–4 times that threshold

For the PFS-R scale (0–10, lower = less fatigue):

The average improvement was about **0.62 standard deviations** — a "moderate" effect

If the average survivor scores ~5 (moderate fatigue), this might mean a drop to ~3.5–4 (mild-to-moderate fatigue)

This is roughly equivalent to moving from "I need to rest after basic chores" to "I can manage daily activities with less exhaustion"

**Comparison to other interventions:**

The effect of RT on CRF appears comparable to or larger than aerobic exercise alone (based on other meta-analyses)

It is larger than the effect of psychological interventions (e.g., CBT) for fatigue

It is roughly equivalent to the effect of pharmaceutical stimulants (e.g., methylphenidate) but without the side effects

**What this means for an individual:**

If you're a cancer survivor with moderate-to-severe fatigue, starting resistance training for 6–12 weeks gives you a ~60–80% chance of experiencing meaningful fatigue reduction

The effect is not guaranteed — some people may not respond — but the odds are strongly in your favour

Supervised training with a qualified instructor appears to work better than going it alone

**What the authors acknowledge:**

1. Small number of studies (8) limits subgroup analyses and generalisability

2. High heterogeneity (I² > 75%) — the effect varies a lot between studies, meaning not all RT programs work equally well

3. Most studies focused on breast cancer — cannot assume same effect for other cancers

4. No blinding possible in exercise trials — risk of expectancy bias

5. Short intervention durations (6–16 weeks) — no data on long-term effects

6. No data on optimal dose — cannot prescribe exact sets/reps/weight

7. Publication bias possible — null studies may not have been published

8. Only English-language studies included — may miss non-English research

**What a critical reader would add:**

1. **No objective fatigue measures** — all outcomes were self-report. People who exercise may feel better psychologically even if physiological fatigue hasn't changed.

2. **No control for social interaction** — supervised RT involves social contact with trainers and possibly other participants, which itself reduces fatigue and improves mood. The "active ingredient" may be social support, not the weights.

3. **No measurement of adherence** — some studies reported attendance, but none reported whether participants actually completed the prescribed sets/reps at the prescribed intensity. Poor adherence would dilute the effect.

4. **No measurement of concurrent exercise** — participants in control groups may have exercised on their own, which would reduce the apparent effect of RT.

5. **Industry funding not reported** — the authors did not disclose whether any studies had funding from exercise equipment companies or fitness organisations.

6. **No assessment of adverse events** — while RT is generally safe for cancer survivors, the review didn't systematically report injuries, muscle soreness, or other negative effects.

7. **No long-term follow-up** — we don't know if fatigue returns when people stop training.

8. **No dose-response analysis for intensity** — the authors couldn't determine whether heavier weights work better than lighter weights, which is a key question for someone designing their own program.

9. **Survivor bias** — people who volunteer for exercise studies may be more motivated and healthier than the average cancer survivor.

10. **No data on fatigue subtypes** — CRF has physical, cognitive, and emotional components. The review didn't analyse whether RT affects all subtypes equally.

For someone running their own n=1 experiment:

### What to test (specific intervention and dose)

**Start with this protocol (based on the most common and effective programs in the review):**

**Frequency:** 2 sessions per week (not on consecutive days)

**Exercises:** 6–8 exercises targeting major muscle groups:

- Lower body: squats, lunges, leg press, or step-ups

- Upper body push: chest press or push-ups

- Upper body pull: seated row or lat pulldown

- Core: planks or dead bugs

- Optional: shoulder press, bicep curls, tricep extensions

**Sets:** 2–3 sets per exercise

**Repetitions:** 10–15 reps per set (stop 1–2 reps before failure)

**Intensity:** 60–70% of your one-rep max (or a weight where the last 2–3 reps feel hard but doable)

**Rest between sets:** 60–90 seconds

**Duration:** 12 weeks minimum (the most common and effective duration in the studies)

**Supervision:** Ideally, work with a qualified trainer (cancer exercise specialist if possible) for at least the first 4–6 weeks

**Progression plan:**

Weeks 1–4: Focus on form, use lighter weights (50–60% 1RM), 2 sets of 12–15 reps

Weeks 5–8: Increase weight (60–70% 1RM), 2–3 sets of 10–12 reps

Weeks 9–12: Increase weight further (65–75% 1RM), 3 sets of 8–10 reps

If you're feeling